Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Oussama M Wazni Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes comparing left atrial appendage (LAA) closure with the WATCHMAN FLX device to oral anticoagulation (OAC) following atrial fibrillation (AF) catheter ablation.Dr Oussama Wazni (The Cleveland Clinic Foundation, Ohio, US) joins us onsite at AHA Conference to discuss the findings from OPTION (NCT03795298).OPTION is a prospective, multi-center, multi… View more
Author(s): Dirk-Jan van Ginkel Added: 1 year ago
ESC Congress 2024 — No benefit of continuing oral anticoagulation during TAVI procedure.Investigator, Dr Dirk-Jan van Ginkel (St Antonius Hospital, NL) joins us to discuss the result of the POPular PAUSE TAVI trial (NCT04437303; St Antonius Hospital). Presented for the first time at ESC 2024, this multicenter, randomized, open-label clinical trial compared the safety and efficacy of continuous… View more
Author(s): Saibal Kar , Harriette Van Spall Added: 2 weeks ago
ACC.26 – Late-breaker host Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Saibal Kar, MD (Los Robles Regional Medical Center, US) to discuss CHAMPION‑AF (NCT04394546), a global randomized trial comparing the WATCHMAN FLX left atrial appendage closure device with non–vitamin K oral anticoagulants in patients with non‑valvular atrial fibrillation at elevated stroke risk… View more
Author(s): Atul Verma Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter… View more